CereVasc announces positive trial results for new NPH treatment
CereVasc, Inc has announced promising initial results from its pilot clinical study evaluating the eShunt System for treating elderly patients with normal-pressure hydrocephalus (NPH), according to a company press release.
The study included 30 patients and achieved its primary safety and efficacy endpoints. No serious adverse events related to the device or procedure were reported within the first 90 days, and 97% of participants exhibited improvements in NPH symptoms, including gait, cognition, and urinary function.
The eShunt System represents a minimally invasive, endovascular approach to treating NPH, potentially offering a safer alternative to traditional open surgical procedures. Dr. Charles Matouk of Yale New Haven Health highlighted that this method “may improve overall care and clinical outcomes,” emphasizing its potential to make treatment accessible to more patients.
In a recent interview with Med Journal 360, Dan Levangie, president and CEO of CereVasc, spoke about the eShunt System and gave an update on the path to potential FDA approval.
The full press release can be found here.
